Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 16

PMID 39409095

Authors

Alfred Najm

Elena-Theodora Moldoveanu

Adelina-Gabriela Niculescu

Alexandru Mihai Grumezescu

Mircea Beuran

Bogdan Severus Gaspar

Affiliations

Soon will be listed here.

Abstract

Since sarcopenia is a progressive condition that leads to decreased muscle mass and function, especially in elderly people, it is a public health problem that requires attention from researchers. This review aims to highlight drug delivery systems that have a high and efficient therapeutic potential for sarcopenia. Current as well as future research needs to consider the barriers encountered in the realization of delivery systems, such as the route of administration, the interaction of the systems with the aggressive environment of the human body, the efficient delivery and loading of the systems with therapeutic agents, and the targeted delivery of therapeutic agents into the muscle tissue without creating undesirable adverse effects. Thus, this paper sets the framework of existing drug delivery possibilities for the treatment of sarcopenia, serving as an inception point for future interdisciplinary studies.

References

Ryu D, Mouchiroud L, Andreux P, Katsyuba E, Moullan N, Nicolet-Dit-Felix A . Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016; 22(8):879-88. DOI: 10.1038/nm.4132. View

Andreana I, Repellin M, Carton F, Kryza D, Briancon S, Chazaud B . Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies. Pharmaceutics. 2021; 13(2). PMC: 7922331. DOI: 10.3390/pharmaceutics13020278. View

Xie W, Xiao G, Hu P, He Y, Lv S, Xiao W . Possible sarcopenia: early screening and intervention-narrative review. Ann Palliat Med. 2020; 9(6):4283-4293. DOI: 10.21037/apm-20-967. View

Chen B, Wang J, Meng X, Luo Z, Liu X, Shen H . Putative Candidate Drug Targets for Sarcopenia-Related Traits Identified Through Mendelian Randomization Analysis of the Blood Proteome. Front Genet. 2022; 13:923429. PMC: 9354522. DOI: 10.3389/fgene.2022.923429. View

Onder G, Penninx B, Balkrishnan R, Fried L, Chaves P, Williamson J . Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002; 359(9310):926-30. DOI: 10.1016/s0140-6736(02)08024-8. View

Tsung T, Tsai Y, Lee H, Chen Y, Lu D . Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases. Int J Mol Sci. 2023; 24(16). PMC: 10455181. DOI: 10.3390/ijms241612976. View

Rizvi S, Saleh A . Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018; 26(1):64-70. PMC: 5783816. DOI: 10.1016/j.jsps.2017.10.012. View

Dinh L, Yan B . Oral Drug Delivery via Intestinal Lymphatic Transport Utilizing Lipid-Based Lyotropic Liquid Crystals. Liquids (Basel). 2024; 3(4):456-468. PMC: 11073766. DOI: 10.3390/liquids3040029. View

Fu B, Yang J, Yang Y, Xia J, He Y, Wang Q . Enhanced Muscle Fibers of by Autologous Nucleic Acid Vaccine. Int J Mol Sci. 2022; 23(13). PMC: 9266527. DOI: 10.3390/ijms23136997. View

10.

Saud Gany S, Chin K, Tan J, Aminuddin A, Makpol S . Curcumin as a Therapeutic Agent for Sarcopenia. Nutrients. 2023; 15(11). PMC: 10255728. DOI: 10.3390/nu15112526. View

11.

Zhang Y, Xu Y, Kong H, Zhang J, Chan H, Wang J . Microneedle system for tissue engineering and regenerative medicine. Exploration (Beijing). 2023; 3(1):20210170. PMC: 10190997. DOI: 10.1002/EXP.20210170. View

12.

Benet L, Hosey C, Ursu O, Oprea T . BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016; 101:89-98. PMC: 4910824. DOI: 10.1016/j.addr.2016.05.007. View

13.

Ishida Y, Kiyokawa Y, Asai T, Oku N . Ameliorating Effects of Sphingomyelin-Based Liposomes on Sarcopenia in Senescence-Accelerated Mice. Biol Pharm Bull. 2016; 39(5):786-93. DOI: 10.1248/bpb.b15-00915. View

14.

Tezze C, Sandri M, Tessari P . Anabolic Resistance in the Pathogenesis of Sarcopenia in the Elderly: Role of Nutrition and Exercise in Young and Old People. Nutrients. 2023; 15(18). PMC: 10535169. DOI: 10.3390/nu15184073. View

15.

Feike Y, Zhijie L, Wei C . Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton). 2021; 4(3):221-233. PMC: 8444957. DOI: 10.1002/agm2.12168. View

16.

Michiue K, Takayama K, Taniguchi A, Hayashi Y, Kogure K . Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis. Pharmaceuticals (Basel). 2023; 16(3). PMC: 10058260. DOI: 10.3390/ph16030397. View

17.

Lo J, U K, Yiu T, Ong M, Lee W . Sarcopenia: Current treatments and new regenerative therapeutic approaches. J Orthop Translat. 2020; 23:38-52. PMC: 7256062. DOI: 10.1016/j.jot.2020.04.002. View

18.

Lach-Trifilieff E, Minetti G, Sheppard K, Ibebunjo C, Feige J, Hartmann S . An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2013; 34(4):606-18. PMC: 3911487. DOI: 10.1128/MCB.01307-13. View

19.

Morvan F, Rondeau J, Zou C, Minetti G, Scheufler C, Scharenberg M . Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc Natl Acad Sci U S A. 2017; 114(47):12448-12453. PMC: 5703284. DOI: 10.1073/pnas.1707925114. View

20.

Coletta G, Phillips S . An elusive consensus definition of sarcopenia impedes research and clinical treatment: A narrative review. Ageing Res Rev. 2023; 86:101883. DOI: 10.1016/j.arr.2023.101883. View